- Home
- PBYI vs III Comparison
PBYI vs III Comparison
Compare PBYI & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- III
- Stock Information
- Founded
- PBYI 2010
- III 2006
- Country
- PBYI United States
- III United States
- Employees
- PBYI N/A
- III N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- III Professional Services
- Sector
- PBYI Health Care
- III Consumer Discretionary
- Exchange
- PBYI Nasdaq
- III Nasdaq
- Market Cap
- PBYI 126.5M
- III 161.3M
- IPO Year
- PBYI N/A
- III 2007
- Fundamental
- Price
- PBYI $2.83
- III $3.18
- Analyst Decision
- PBYI Strong Buy
- III Buy
- Analyst Count
- PBYI 1
- III 1
- Target Price
- PBYI $7.00
- III $3.50
- AVG Volume (30 Days)
- PBYI 257.4K
- III 98.1K
- Earning Date
- PBYI 10-31-2024
- III 11-07-2024
- Dividend Yield
- PBYI N/A
- III 5.66%
- EPS Growth
- PBYI N/A
- III N/A
- EPS
- PBYI 0.18
- III N/A
- Revenue
- PBYI $219,143,000.00
- III $266,491,000.00
- Revenue This Year
- PBYI N/A
- III N/A
- Revenue Next Year
- PBYI N/A
- III $11.73
- P/E Ratio
- PBYI $15.55
- III N/A
- Revenue Growth
- PBYI N/A
- III N/A
- 52 Week Low
- PBYI $2.13
- III $2.92
- 52 Week High
- PBYI $7.73
- III $4.98
- Technical
- Relative Strength Index (RSI)
- PBYI 59.52
- III 46.88
- Support Level
- PBYI $2.79
- III $3.13
- Resistance Level
- PBYI $2.93
- III $3.25
- Average True Range (ATR)
- PBYI 0.12
- III 0.07
- MACD
- PBYI 0.04
- III 0.00
- Stochastic Oscillator
- PBYI 80.77
- III 20.83
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.